ClinicalTrials.gg
CompletedNCT07070297Updated Jul 17, 2025

A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses

A Phase 1 interventional study of XKH001 Injection in Asthma Patients, sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry.
  • Registered 11 months after the study started (first participant enrolled Dec 2023, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
178th of 182
12 · median 203
Started
2023
with 22 others
Phase 1
31 of 251
3 open now
Registered
190th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 178th largest by enrollment of the 182 interventional ones that give a count, is one of 23 that started in 2023, is one of 31 in phase 1, and was the 190th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm, open-label clinical study. A total of 12 patients with allergic asthma are planned to be enrolled to receive XKH001 600 mg Q4W administration for the assessment of the safety, immunogenicity, PK, and PD characteristics of multiple doses.

Read the detailed description

This study is a single-arm, open-label clinical study. A total of 12 patients with allergic asthma are planned to be enrolled to receive XKH001 600 mg Q4W administration for the assessment of the safety, immunogenicity, PK, and PD characteristics of multiple doses.

The screening period will not be more than 28 days (i.e., 4 weeks). The treatment period will be 12 weeks, and the follow-up period will be 12 weeks.

All recruited patients with allergic asthma will undergo various screening procedures within 28 days prior to the first dose, and those who pass the screening will be sequentially enrolled.

Patients who are enrolled in the study will be admitted to the study site on the day before each scheduled dose (D-1, D28, and D56) to complete the necessary pre-dose safety assessments and receive XKH001 subcutaneous (SC) injections on D1, D29, and D57.

The patient will undergo regular safety assessment procedures (AE/SAE, vital signs, physical examination, laboratory tests, 12-lead electrocardiogram (ECG), etc.), FeNO, pulmonary function tests (FEV1 PD20 Mch), sputum induction, and other blood sample collections (PK, PD, and ADA) during the treatment period (D1-D85) and the subsequent 12-week follow-up period (\~D169).

Visits and procedures at screening, treatment, and follow-up are detailed in the Schedule of Assessment.

If a subject discontinues treatment prematurely, the "Early Withdrawal" visit and all procedures will be performed, the same as D169.

If asthmatic patients test positive for seasonal allergens (such as pollen), they should avoid the allergy season when enrolling in the study.

03

Conditions studied

  • Asthma Patients

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be eligible to participate in the study, a subject must meet all of the following criteria:

    1. Subjects who voluntarily sign a written form (ICF) and are able to complete the study as required by the protocol;
    2. Male or female subjects aged 18 to 65 years (inclusive), with a (BMI) between 18 and 30 kg/m2 (inclusive);
    3. Subjects diagnosed with asthma according to the Guidelines for the Prevention and Treatment of Bronchial Asthma (China) 2020 with an asthma course (since the first incidence) of at least 6 months and meet the following requirements at the same time:

      Subjects with a positive reaction to at least 1 type of aeroallergen (such as dust mites, pollen, mold, or animal hair) in the skin prick test or allergen-specific IgE testing record before screening or during screening; Subjects with the (ULN) at the site ≤ total serum IgE ≤ 1000 IU/mL at screening; Subjects with the bronchial provocation test PD20 Mch ≤ 1.075 mg; Subjects with FEV1 ≥ 70% of the predicted value at screening;

    4. Subjects with occasional asthma symptoms (≤ 2 times/week), treated only with ICS-LABA inhalation (Symbicort®, budesonide and formoterol fumarate powder for inhalation, 1 inhalation per dose) as needed. The subject does not need to use other asthma medications on a daily basis, and other asthma medications have been discontinued before screening:

      Inhaled and nasal should be discontinued for 4 weeks; Leukotriene receptor antagonists should be discontinued for 2 weeks; Long-acting β-receptor agonists should be discontinued for 2 weeks; Anticholinergic drugs should be discontinued for 2 weeks; Antihistamines should be discontinued for 2 weeks; Theophylline drugs should be discontinued for 1 week.

    5. Subjects with normal laboratory test and 12-lead results or with abnormalities determined by the investigator not to be at screening;
    6. Women of must have a negative pregnancy test result and not be in the lactation period at screening; regardless of sex, all participants must agree to have no plans for reproduction during the study and within 6 months after the study, voluntarily adopt effective measures, and have no plans for sperm/egg donation.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria must be excluded from this study:

    1. Subjects who are current smokers or with a smoking history of > 10 pack-years. Subjects who have quit smoking need to have quit smoking for at least 12 months before enrollment;
    2. Subjects with hospitalization or emergency visits due to respiratory system and/or asthma-related conditions within 6 months before screening;
    3. Subjects with worsening or exacerbation of asthma, or the use of systemic therapy within 6 weeks before or during screening;
    4. Subjects with a history of alcoholism or drug abuse;
    5. Subjects who are allergic to the product or any component of the formulation of the investigational product or have a history of allergy to protein drugs;
    6. Subjects with elevated total IgE due to reasons other than allergens (e.g. parasitic infections and hematological disorders);
    7. Subjects who have undergone allergen-specific immunotherapy or used within 3 months before screening;
    8. Subjects who have used biologics (such as monoclonal antibodies), including investigational biologics, within 6 months before screening;
    9. Subjects who have received any anti-IgE antibody treatment or bronchial thermoplasty within 12 months before screening;
    10. Subjects who have received live (attenuated) viral/bacterial vaccines or intravenous (IV) immunoglobulins (IgG) within 4 weeks before screening;
    11. Subjects with respiratory system infection or have received a major surgery within 8 weeks before screening;
    12. Subjects with a combination of other lung diseases such as , bronchiectasis, or lung fibrosis;
    13. Subjects with a history of to choline, such as myocardial infarction or stroke within the past 3 months, known heart disease, uncontrolled hypertension, aortic or brain aneurysm;
    14. Subjects with neoplasm malignant within 5 years before screening or current neoplasm malignant;
    15. Subjects with a history of diseases, known family history of inherited immunodeficiency disorders, or recurrent infections suggestive of possible immunodeficiency;
    16. Subjects who had or currently have active tuberculosis, or active infection requiring hospitalization or IV antibiotic treatment within 3 months before screening;
    17. Subjects with positive in 5 items of hepatitis B serology (if HBsAg is negative, HBcAb is positive, and HBsAb is negative, HBV-DNA quantitative test is required to be performed [the subject will be excluded if the test result is positive]), antibody, treponema pallidum antibody, and antigen/antibody;
    18. Subjects who have participated in other investigational drug clinical studies within 30 days or 5 half-lives of the study drug (whichever is longer). If a subject has received an investigational drug of a biological product, e.g., a monoclonal antibody, the subject is required to have received the biological product at least 6 months before the screening visit;
    19. Subjects with severe, progressive, or uncontrolled diseases such as liver, kidney, gastrointestinal, cardiovascular, hematopoietic, genitourinary, endocrine, nervous, immune system disorders, and other conditions that investigators consider unsuitable for inclusion in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Experiment

    Patients who are enrolled in the study will be admitted to the study site on the day before each scheduled dose (D-1, D28, and D56) to complete the necessary pre-dose safety assessments and receive XKH001 subcutaneous (SC) injections on D1, D29, and D57.

    Drug: XKH001 Injection

Interventions

  • Dosage: 600 mg Q4W (D1, D29 and D57) Method of administration: the drug will be administered by SC injection in an area 3 cm away from and within 5 cm around the umbilicus of the abdomen. Sites with skin damage, inflammation, ulceration, rash and scar should be avoided. Subjects should be closely observed for reactions within 4 h after dosing.

06

What researchers measure

Primary outcomes

  1. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.

    Changes from baseline in FEV1 PD20 Mch after treatment

    Time frame: Day43, Day85

  2. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.1

    Incidence of AEs/SAEs

    Time frame: Day169

  3. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.2

    Severity of AEs/SAEs

    Time frame: Day169

Secondary outcomes

  1. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.1

    Incidence of ADAs and NAb \[detect NAb when ADA positive\];

    Time frame: Day169

  2. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.2

    FeNO (exhaled nitric oxide concentration);

    Time frame: Day169

  3. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.3

    Total IgE;

    Time frame: Day169

  4. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.4

    Levels of IL-25-related cytokines in sputum supernatants (same as serum).

    Time frame: Day169

  5. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.6

    Cmax,ss,

    Time frame: Day169

  6. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.7

    Cmin,ss

    Time frame: Day169

  7. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.8

    Cavg,ss

    Time frame: Day169

  8. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.9

    AUC0-inf,ss

    Time frame: Day169

  9. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.10

    AUC0-t,ss,

    Time frame: Day169

  10. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.11

    Tmax,ss,

    Time frame: Day169

  11. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.12

    t1/2,ss

    Time frame: Day169

  12. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.13

    AUCtau,

    Time frame: Day169

  13. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.14

    %AUCex

    Time frame: Day169

  14. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.15

    λz,ss

    Time frame: Day169

  15. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.36

    Vz,ss/F

    Time frame: Day169

  16. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.16

    CLss/F

    Time frame: Day169

  17. To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.17

    MRT;

    Time frame: Day169

  18. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.20

    LYM ratios in sputum;

    Time frame: Day169

  19. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.22

    Whole blood EOS count

    Time frame: Day169

  20. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.23

    Whole blood NEU count

    Time frame: Day169

  21. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.24

    Whole blood LYM count

    Time frame: Day169

  22. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.25

    Whole blood MON count;

    Time frame: Day169

  23. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.26

    Levels of IL-25 in serum

    Time frame: Day169

  24. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.27

    Levels of TARC in serum

    Time frame: Day169

  25. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.28

    Levels of IL-8 in serum

    Time frame: Day169

  26. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.29

    Levels of MIP1β in serum

    Time frame: Day169

  27. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.30

    Levels of Eotaxin in serum

    Time frame: Day169

  28. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.31

    Levels of CXCL1 (KC/GROα) in serum

    Time frame: Day169

  29. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.32

    Levels of Eotaxin-3 in serum

    Time frame: Day169

  30. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.33

    Levels of IL-4 in serum

    Time frame: Day169

  31. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.34

    Levels of IL-5 in serum

    Time frame: Day169

  32. To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.35

    Levels of IL-13 in serum;

    Time frame: Day169

07

Study locations

1 site
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Oct 2024, 9 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 9 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Jul 17, 2025
StartActual
Dec 26, 2023
Primary completionActual
Oct 10, 2024
CompletionActual
Dec 20, 2024
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07070297
Lead sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Dec 26, 2023
Primary completion
Oct 10, 2024
Completion
Dec 20, 2024
Last update
Jul 17, 2025

Study contacts

Wen Li, Dr
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XKH001

Start the discussion